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Abstract According to the Dutch Guideline on Heredi-
tary Colorectal Cancer published in 2008, patients with
recently diagnosed colorectal cancer (CRC) should
undergo microsatellite instability (MSI) testing by a
pathologist immediately after tumour resection if they are
younger than 50 years, or if a second CRC has been
diagnosed before the age of 70 years, owing to the high
risk of Lynch syndrome (MIPA). The aim of the present
MIPAPS study was to investigate general distress and
cancer-specific distress following MSI testing. From March
2007 to September 2009, 400 patients who had been tested
for MSI after newly diagnosed CRC were recruited from
30 Dutch hospitals. Levels of general distress (SCL-90)
and cancer-specific distress (IES) were assessed immedi-
ately after MSI result disclosure (T1) and 6 months later
(T2). Response rates were 23/77 (30%) in the MSI-positive
patients and 58/323 (18%) in the MSI-negative patients.
Levels of general distress and cancer-specific distress were
moderate. In the MSI-positive group, 27% of the patients
had high general distress at T1 versus 18% at T2 (p = 0.5),
whereas in the MSI-negative group, these percentage were
14 and 18% (p = 0.6), respectively. At T1 and T2, cancer-
specific distress rates in the MSI-positive group and MSI-
negative group were 39 versus 27% (p = 0.3) and 38
versus 36% (p = 1.0), respectively. High levels of general
distress were correlated with female gender, low social
support and high perceived cancer risk. Moderate levels of
distress were observed after MSI testing, similar to those
found in other patients diagnosed with CRC. Immediately
after result disclosure, high cancer-specific distress was
observed in 40% of the MSI-positive patients.
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Introduction
Each year, more than one million patients are diagnosed
with colorectal cancer (CRC) worldwide and approxi-
mately 3% have Lynch syndrome [1]. Identifying Lynch
syndrome is highly relevant, because surveillance reduces
morbidity and mortality in family members who carry a
mutation in one of the mismatch repair genes [2]. Patients
at risk for Lynch syndrome can be detected effectively with
a microsatellite instability (MSI) test, which is a molecular
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genetic test on CRC tumour DNA [3–6]. In Lynch syn-
drome, almost all CRCs show high (positive) MSI.
In patients diagnosed with CRC at a relatively young
age, a positive MSI test is strongly associated with genetic
susceptibility [7] and can therefore be used as an indicator
for Lynch syndrome. Generally, patients with an MSI-
positive tumour have good overall prognoses [8, 9]. In the
past, people underwent MSI testing after referral to a
clinical genetic department, because of multiple CRCs in
the family. However, only a minority of patients with
Lynch syndrome were identified by their family history
[10–13]. A new cost-effective and efficient test (MSI-
testing-indicated-by-a-Pathologist (MIPA) procedure) [5,
14, 15] has enhanced the recognition of patients at risk for
Lynch syndrome [5, 14, 15]. Pathologists perform MSI
testing on recently diagnosed patients if they meet one of
the following MIPA criteria: (1) CRC diagnosed before the
age of 50 years; (2) second CRC diagnosed before the age
of 70 years [5, 16, 17]. The MSI test result is reported to
the surgeon. If the result is positive, the surgeon is advised
to consider referring the patient for genetic counselling,
which might include germline DNA analysis. One year
before the introduction of the MIPA procedure, only 30%
of patients at risk for Lynch syndrome were recognized as
such by the traditional method based on family history
[18]. Other studies also reported that family history did not
adequately identify patients at risk for Lynch syndrome
[10–13]. After the introduction of the MIPA procedure,
performed by multidisciplinary teams that include surgeons
and pathologists, the recognition of patients at risk for
Lynch syndrome has increased substantially [15].
The MIPA procedure implies that CRC patients are
simultaneously confronted with (1) the diagnosis of cancer
and its treatment; (2) a possibly hereditary predisposition
for Lynch syndrome and (3) the need to inform children
and relatives about their possible cancer risks. CRC itself is
known to be responsible for considerable physical and
psychosocial morbidity [19]. The question therefore arises:
To what extent will MSI testing add to this distress? Newly
diagnosed CRC patients who were immediately offered
genetic testing for hereditary CRC considered the test and
the timing to be highly acceptable [20]. However, little is
known about the actual psychosocial consequences of
discussing a high genetic risk for Lynch syndrome with
CRC patients during the treatment phase. The aim of the
present study was to investigate general distress and can-
cer-specific distress in these patients. Social support and
cancer risk perception were also studied as possible pre-
dictors of distress levels [21–24]. Furthermore, in the rel-
atively young patients with CRC, the reactions of the
partner were measured twice in the 6 months following
MSI testing.
Methods
Patients and design
A prospective multi-centre study was performed in
patients recently diagnosed with CRC to assess their
psychological and cancer-specific distress and the
response of their partner following MSI testing [5].
Inclusion criteria were (1) patient younger than 50 years
at CRC diagnosis, or (2) second CRC diagnosed before
the age of 70 years.
Psychological assessment took place using question-
naires immediately after MSI result disclosure (T1) and
6 months later (T2). Patients who had been diagnosed more
than 6 months earlier were excluded. We chose a follow-up
of 6 months because some patients need adjuvant therapy
that can involve a treatment trajectory of 12 months or
more [25]. As adjuvant therapy might also affect psycho-
logical distress levels, this variable was included in our
analyses.
Procedure
Between September 2006 and March 2007, 30 Dutch
hospitals were invited to participate in the MIPAPS
(Psychosocial Impact MIPA Strategy) study. Hospitals
were selected based on their previous participation in the
MIPA implementation study [15] and several additional
hospitals were also approached in the neighbouring
regions. From March 2007 to September 2009, we iden-
tified 400 patients who had been newly diagnosed with
CRC and undergone an MSI test. The patient’s surgeon
was requested to invite the MIPA patient and his or her
partner to participate in the MIPAPS study. The majority
of hospitals that took part in the study could not perform
the MSI-test themselves and sent the tumour tissue sam-
ple to a specialized centre, e.g. the Department of
Pathology of the Radboud University Medical Centre in
Nijmegen. Once the result was available, it was sent to
the pathologist, who then passed it on to the surgeon.
Consequently, it was not until about some months after
surgery that the surgeon could communicate the MSI test
result to the patient. The time limit for inclusion by the
treating physician was 6 months after CRC diagnosis. As
a result of medical confidentially, we were unable to
determine exactly how many patients had been invited by
their surgeon and whether or not they had declined the
invitation. As soon as written informed consent was
received, questionnaires were sent to the patient and his
or her partner. The study was approved by the Ethical
Committee Arnhem-Nijmegen (CMO No. 2006/042).
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Assessments
Distress
The Symptom Check List-90 (SCL-90) with a 5-point
Likert scale (scores 1–5) was used to assess psychopa-
thology. A total SCL-90 score of more than 160 is indic-
ative of high psychological distress, while a score of more
than 200 is indicative of a psychiatric disorder [26, 27].
The Profile of Mood States-Short Form [28] was used to
assess affective states. Items were rated on a 5-point scale
(0–4) and produced scores of 0–32 for depression, 0–28 for
anger, 0–24 for fatigue, 0–24 for tension and 0–20 for
vigour. This questionnaire has previously been validated
for cancer patients [29].
Cancer-specific distress
The Impact of Event Scale (IES) [30, 31] was used to
assess CRC-specific distress. All 15 items were rated on a
4-point Likert scale (scores 0, 1, 3, 5). Total IES scores
could range from 0 to 75. A total IES score of 9–25 is
indicative of moderate adaptation difficulties, while a score
C26 is considered to be indicative of clinical adaptation
difficulties and reflect a need for [32] psychological or
psychiatric support.
Colorectal cancer risk perception
Lifetime risk of CRC was measured with a single question
from the Cancer Risk Perception List [22–24]: ‘‘My risk of
having colorectal cancer again is….’’. The patients marked
their risk perception on a Visual Analogue Scale (VAS
0–100%). Absolute risk ranges were classified as follows:
0–20 (low); 20–40 (moderate); 40–60 (fairly high); 60–80
(high); 80–100 (very high).
Social support
Social support was assessed on a 4-point Likert Scale with
the Dutch self-report Inventory for Social Support (ISS).
The inventory comprises three scales: (1) potential emo-
tional support: range 5–20, moderate 13–15; (2) actual
emotional support: range 3–12, moderate 5–7 and (3) vis-
its: range 2–8, moderate 5–6 [33]. Higher scores indicate
greater social support.
Partner’s reaction to providing care and support
for the cancer patient
At T1 and at T2, the patient’s partner was invited to
complete two questionnaires. The effect of providing care
and support for the cancer patient was measured with the
Caregiver Reaction Assessment (CRA-D) using the 7-item
subscale self-esteem. Perceived impact was rated on a
5-point Likert scale. Higher scores represented lower self-
esteem [34, 35]. Perceived distress caused by the provision
of informal care was measured using the validated 9-item
Dutch self-report questionnaire EDIZ (one dimensional
assessment of care burden) [36]. Total scores were inter-
preted in three categories: 9–20 (low burden), 21–32
(overburdened) and 33–45 (severely overburdened) [23,
37].
Statistical analysis
Demographic and clinical characteristics of the MSI-posi-
tive group and MSI-negative group were analysed using the
independent T test for the continuous variables and Pear-
son’s exact v2 test and McNemar’s test for the categorical
variables. General linear models for repeated measure-
ments (GLM RP) were used to test for differences in
psychological distress and partner’s care burden over time.
Correlations between distress and demographic variables,
social support and cancer risk perception were assessed by
Spearman’s Rank Correlation, represented by Spearman
rho (q). SPSS 16.0 statistical package was used to analyse
the data.
Results
Patient characteristics
Response rates of the MSI-positive patients (MSI-high
CRC) and MSI-negative patients (microsatellite stable-
CRC or MSI-low CRC) were 23/77 (30%) and 58/323
(18%), respectively. No significant differences were found
in age at diagnosis (t = 0.095; p = 0.8) or gender
(t = 0.076; p = 0.6) between the participants and the non-
responders. The participating CRC patients (n = 81) were
aged 48 ± 10 years. Data were obtained 5 ± 3 months
after CRC diagnosis (T1); 50% of the participants were
male. Demographic and medical characteristics (T1) of the
MSI-positive and MSI-negative groups are shown in
Table 1. Tumour characteristics were significantly differ-
ent between the two groups. As expected, more patients in
the MSI-positive group had a right-sided tumour and a low
TNM tumour stage. Moreover, fewer of these MSI-positive
patients had received adjuvant therapy. Partner response
rates in the MSI-positive and MSI-negative patients were
56% (n = 13) and 63% (n = 37), respectively (28 women,
22 men). Surgeons did not always know whether a patient
had a partner or not, so these percentages were based on all
the patients who participated.
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Distress
At T1, psychological distress scores (SCL-90) in the MSI-
positive group and MSI-negative group were within the
same range (Table 2). Mean scores of psychological dis-
tress were moderate at T1 (131 ± 38) and T2 (131 ± 46),
which was lower than in breast cancer patients (151 ± 45)
and haematological cancer patients (145 ± 33), but similar
to the scores in patients with other solid tumours
(130 ± 25) [23, 38]. In the course of the study, the results
of the GLM for repeated measures analysis showed dif-
ferences in psychological distress between the two groups
(Fig. 1a). A significant interaction effect was found
between the MSI test result and the time of assessment,
which indicated a decrease in psychological distress in the
MSI-positive group and an increase in the MSI-negative
group between T1 and T2 (F(1,71) = 4.91, p = 0.03).
Although the differences were statistically significant, the
changes in psychological distress may not be clinically
relevant, because the mean distress levels did not reach the
cut-off score of 160 (indicative of high distress). At T1,
almost twice as many patients in the MSI-positive group
reported high psychological distress (27%) than in the
MSI-negative group (14%), but this difference was not
statistically significant. In the MSI-positive group, per-
centages of patients with high general distress were 27% at
T1 and 18% at T2 (McNemar test, exact p = 0.5); in the
MSI-negative group, these percentages were 14% at T1 and
18% at T2 (McNemar test, exact p = 0.6). Thus, at T2,
18% of the patients in the two groups still reported high
psychological distress.
Individual psychological distress levels in the MSI-
positive group and MSI-negative group are shown in
Fig. 2. Per patient, psychological distress generally
remained stable over time in the two groups. Psychological
distress at T1 was significantly correlated with female
gender (q = 0.269, p = 0.02), low social support (poten-
tial support q = -0.298, p = 0.01, visits q = -0.263,
p = 0.03) and high CRC lifetime risk perception
(q = 0.318, p = 0.006). No significant correlations were
found between the levels of psychological distress and
TNM stage, or between the levels of psychological distress
and adjuvant therapy.
Table 2 shows the mean levels of mood states (POMS)
in the MSI-positive group and MSI-negative group at T1
and T2. All mean affective states were within the same
range as those observed in other patients diagnosed with
cancer [29]. No significant differences were found between
the MSI-positive group and MSI-negative group.
Cancer-specific distress
At T1, cancer-specific distress levels in the MSI-positive
group and MSI-negative group were within the same range
(Table 2). Mean scores of cancer-specific distress in the
study sample were moderate at T1 (21 ± 15) and T2
(21 ± 17). Results of the GLM for repeated measures
analysis showed that over time, there were no significant
differences in cancer-specific distress levels between the
two groups. At T1, 38% of the total group reported high
cancer-specific distress (IES C 26); the separate rates were
39 and 38% in the MSI-positive group and MSI-negative
group, respectively. At T1 and T2, cancer-specific distress
rates in the MSI-positive group and MSI-negative group
were 39 versus 27% (McNemar test, exact p = 0.3) and 38
versus 36% (McNemar test, exact p = 1.0), respectively.
At T1, cancer-specific distress scores were significantly
correlated with female gender (q = 0.328, p = 0.005). No
significant correlations were found between the cancer-
specific distress levels and TNM stage, or between the
cancer-specific distress levels and adjuvant therapy.
Social support and cancer risk perception
At T1 and T2, mean social support levels in the MSI-
positive group and MSI-negative group were moderate
compared to a norm group of healthy adults [33].
Table 1 Baseline characteristics of the patients
MSI-positive
groupa
MSI-negative
group
n = 23 n = 58 p
Patient characteristics
Age at cancer diagnosis 48 ± 10 48 ± 12 nsb
Male 12 (52%) 29 (50%) nsc
Married or cohabiting 23 (100%) 50 (86%) nsc
Having children 21 (91%) 49 (89%) nsc
Educational level [ high
school
14 (61%) 30 (52%) nsc
Religious 17 (74%) 34 (59%) nsc
CRC diagnosed below
50 year
15 (65%) 38 (66%) nsc
Second CRC diagnosed
below 70 year
7 (32%) 20 (35%) nsc
Tumour characteristics
Right sided tumour location 11 (50%) 15 (26%) 0.06c#
TNM stage I or II 16 (73%) 26 (45%) 0.04c*
Adjuvant therapy 12 (55%) 40 (78%) 0.04c*
a MSI-positive means that the MSI-test in the tumor is positive and is
performed at the initiative of a pathologist, either because the CRC
was diagnosed below 50 years or because it was the second CRC
below 70 years
b Independent samples T test
c Pearson chi-square test
# p \ 0.1; * p \ 0.05; ns not statistically significant
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Additionally, there were no significant differences in social
support levels between the two groups (Table 2). Table 2
shows that at T1, patients in the two groups reported a
fairly high-risk perception of being rediagnosed with CRC
in the near future. At T2, risk perception had increased
significantly in the total group from 43 to 50% (t = 2.237;
p = 0.03); the separate rates of increase were 43–48%
(t = 1.409; p = 0.2) in the MSI-negative group, versus
44–53% (t = 1.948; p = 0.07) in the MSI-positive group.
Partner’s reaction to providing care and support
for the cancer patient
Results of the GLM for repeated measures analysis showed
significant time effects in the CRA-D and EDIZ ques-
tionnaires completed by the partner (F(1, 48) = 7.00,
p = 0.01 and F(1, 46) = 4.61, p = 0.04, respectively).
This indicated that the negative impact of providing care
decreased in the MSI-positive group and MSI-negative
group (Fig. 1b). The partners’ self-esteem (CRA-D) was
within the same range as that in the partners of patients
with other types of cancer [39] (Table 2). Distress caused
by providing informal care (EDIZ) was reported by 49 and
38% of the partners at T1 and T2, respectively. No sig-
nificant differences in self-esteem and distress were found
between the MSI-positive group and MSI-negative group.
No significant correlation was found between the partner’s
gender and the reaction to providing care.
Advantages of the MIPA procedure
The MIPA procedure greatly enhances the efficiency of
genetic counselling, because there is an increased risk that
MSI-high CRC patients are carriers of the mismatch repair
(MMR) gene mutation. In our group of 22 MSI-high CRC
patients (45%), ten were subsequently found to carry a
mutation in one of the MMR genes (n = 6 MLH1, n = 2
MSH6 and n = 2 PMS2). In 6 of these patients (27%), MSI
Table 2 Psychosocial outcomes of MSI-positive (n = 22*) and MSI-negative (n = 51*) patients and their partners (n = 13 and n = 37
respectively), immediately after MSI-test disclosure (T1) and 6 months later (T2)
MSI-positive patientsa MSI-negative patients
T1 T2 D T1 T2 D
CRC patients
Psychological distressb 137 ± 45 127 ± 51 -10 ± 27 129 ± 37 133 ± 43 4 ± 24
Cancer specific distressc 22 ± 22 18 ± 17 -4 ± 14 21 ± 15 22 ± 17 1 ± 13
Depressiond 4 ± 6 3 ± 5 -1 ± 4 3 ± 4 5 ± 6 2 ± 5
Angerd 5 ± 6 5 ± 6 0 ± 4 3 ± 4 5 ± 6 1 ± 4
Fatigued 8 ± 6 5 ± 6 -3 ± 5 6 ± 6 6 ± 6 0 ± 4
Tensiond 5 ± 5 4 ± 5 -1 ± 3 3 ± 4 5 ± 5 1 ± 4
Vigord 9 ± 4 11 ± 5 2 ± 5 9 ± 5 10 ± 5 1 ± 5
Cancer risk perceptione 44 ± 23 53 ± 23 10 ± 23 43 ± 21 48 ± 22 5 ± 24
Social supportf
Potential emotional trust 16 ± 4 16 ± 4 0 ± 4 17 ± 4 16 ± 4 0 ± 3
Actual emotional trust 7 ± 2 7 ± 2 0 ± 2 7 ± 2 6 ± 2 0 ± 2
Visits 6 ± 1 6 ± 2 0 ± 1 6 ± 1 6 ± 1 0 ± 1
Partners of CRC patients
Caregiver’s esteemg 29 ± 4 27 ± 5 -3 ± 5 29 ± 3 28 ± 4 0 ± 4
Perceived stress by careh 21 ± 4 18 ± 5 -2 ± 5 23 ± 6 21 ± 5 -1 ± 6
a MSI-positive means that the MSI-test in the tumor is positive and is performed at the initiative of a pathologist, either because the CRC was
diagnosed below 50 years of because it was the second CRC below 70 years. D, difference scores (T2-T1), based on the original scores before
rounding
b SCL-90
c IES-CRC
d POMS
e Life time risk to get CRC again
f ISB
g CRAD
h EDIZ
* Patients who filled in both questionnaires (T1 and T2)
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was explained by non-hereditary hypermethylation of the
MLH1 promoter. The DNA test result at T2 was not sig-
nificantly correlated with psychological distress or with
cancer-specific distress.
Discussion
To our knowledge, this is the first multicentre study on
psychological distress in patients recently diagnosed with
Fig. 1 a Course of mean levels
of psychological distress in 22
MSI-positive^ and 51 MSI-
negative patients with CRC.
b Course of mean levels of
caregiver experiences in 13
partners of MSI-positive^
patients and 37 partners of MSI-
negative patients with CRC, a
lower CRA-D score indicates
higher caregiver’s esteem, a
higher EDIZ score indicates
higher perceived distress by
informal care. a SCL-90:
p \ 0.03 (interaction-effect);
b CRAD: p = 0.01 (time-
effect), EDIZ: p = 0.04 (time-
effect). ^ MSI-positive means
that the MSI-test in the tumour
is positive and is performed at
the initiative of a pathologist,
either because the CRC was
diagnosed below 50 years or
because it was the second CRC
below 70 years
Fig. 2 Psychological distress
per MIPAPS patient at T1 and
T2. A score above the cut off of
160 (dotted line) indicates high
psychological distress
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CRC following genetic pre-screening for Lynch syndrome
by MSI testing. Our data indicated that disclosure of the
MSI test result was not followed by high levels of distress
in the majority of these patients. This is in agreement with
a previous study in which a shorter time interval between
the cancer diagnosis and genetic pre-screening for Lynch
syndrome was not related to higher psychological distress
[40]. Data from our patients in the MIPAPS pilot study
showed that the advantages of early screening, e.g. timely
medico-prevention strategies for their children, outweighed
any possible disadvantages [41]. These two studies point in
the same direction, namely that pre-screening for Lynch
syndrome by MSI testing in patients recently diagnosed
with CRC is justifiable from a psychological point of view.
Distress and cancer-specific distress levels were mod-
erate in the MSI-positive group and MSI-negative group.
However, it is important to note that a minority of our
patients with CRC did report high levels of general psy-
chological distress and cancer-specific distress after MSI
testing. These high levels of distress decreased over time in
the MSI-positive group and remained stable in the MSI-
negative group. Six months after MSI test result disclosure,
i.e. almost a year after CRC diagnosis, about 20% of the
CRC patients were still highly distressed and about 40%
were still experiencing high cancer-specific distress.
Although the levels of general psychological distress and
cancer-specific distress were independent of the MSI test
result, they were found to be related to female gender.
General psychological distress was also related to low
social support and high cancer risk perception. In our
study, the overall prevalence of high general psychological
distress was lower than that in a previous study in which
32% of the newly diagnosed patients reported high distress
[27]. The literature has shown that two-thirds of patients
with cancer will adapt to their diagnosis without any psy-
chological intervention [27]. Initial psychological adapta-
tion to the diagnosis of cancer is strongly influenced by
pre-existing psychosocial factors [42]. These results high-
light the necessity to identify patients with high levels of
distress. In our opinion, psychological screening and if
indicated, subsequent professional support, should take
place soon after CRC diagnosis to avoid or reduce long-
term distress.
The results of our study on young patients recently
diagnosed with CRC are in line with those from studies on
patients recently diagnosed with breast cancer who were
actively approached for genetic counselling and testing.
Overall, no additional short-term or long-term psycholog-
ical distress was found in this group of patients [43, 44].
One of the explanations given previously was that the
possibly hereditary nature of cancer is not nearly as dis-
tressing as the diagnosis of cancer itself [45]. According to
our clinical observations, a genetic diagnosis may help
patients to understand at least a part of the origin of CRC
and reduce psychological distress. However, these obser-
vations need to be confirmed by further research.
Another explanation might be that in general, MSI-posi-
tive CRC patients have good overall prognoses and there is
often less need for adjuvant therapy, as was the case in our
study. Therefore, patients who have a high risk of Lynch
syndrome may have psychologically compensated for any
potentially negative effects based on these factors. The rea-
son why levels of distress and cancer-specific distress
remained stable over time in the MSI-negative CRC patients
might lie in their poorer prognoses and more general need for
adjuvant therapy. However, we could not detect any corre-
lation between adjuvant therapy and psychological distress.
The partners of the patients in the MSI-positive group
and MSI-negative group showed moderate to high levels of
self-esteem. These levels were comparable with those
described in the literature on partners of patients with CRC
[35] or other types of cancer [39]. In the two groups, levels
of perceived distress decreased over time. This was in
concordance with the previous literature in which the
treatment phase was experienced as the most stressful
period, as it involved the greatest need for emotional and
informational support [46].
One limitation of our study was the low response rate in
the eligible patients. This may have biased our results,
especially if the surgeons had consciously avoided
recruiting patients with a (very) poor prognosis or emo-
tional problems. Such bias would have resulted in under-
estimation of psychological distress. At present, we cannot
assess whether bias was present. However, we note that in
our sample, the levels of psychological distress were lower
than those described in the literature. Another reason for
the low response rate may have been the complex logistic
inclusion procedure [15], if communication of the test
result to the patient exceeded the inclusion criterion of
6 months. In some cases, it took several months before the
MSI-test report, written by the pathologist, was sent to the
surgeon and a number of weeks more before the patient
was contacted. Another limitation of our study was that no
firm conclusions could be drawn, because the large number
of tests increased the possibility of a type I error, which we
have not corrected for.
Despite some methodological concerns, we can con-
clude that moderate levels of distress were present fol-
lowing MSI testing in patients recently diagnosed with
CRC. These levels were similar to those in other patients
diagnosed with CRC [27, 47, 48]. High cancer-specific
distress was observed in 40% of the MSI-positive patients
and was significantly correlated with female gender.
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